Bone Loss Prevention With Zoledronic Acid or Denosumab in Critically Ill Adults
报名条件(概要)
- 年龄:50 Years – 不限
- 性别:不限
- 健康志愿者:不接受
完整入排标准请以官方页面为准。
开展国家/地区
Australia、New Zealand
研究药物 / 干预措施
Denosumab 60 MG/ML、Zoledronic Acid 5Mg/Bag 100Ml Inj、Sodium Chloride 0.9% or 5% Dextrose Intravenous、Sodium Chloride 0.9% Injection
申办方
Australian and New Zealand Intensive Care Research Centre
研究简介(原文)
The Bone Zone trial is a prospective, multi-centre, double-blind, phase II, randomised controlled trial evaluating the effect of denosumab or zoledronic acid compared to placebo on change in bone mineral density over one year in women aged 50 years or older and men aged 70 years or older requiring admission to intensive care for greater than 24 hours. 450 women aged 50 years or older and men aged 70 years or older, admitted to intensive care for greater than 24 hours will be recruited into the study from participating study centres.
适应症
主动联系研究团队
这项试验目前在中国大陆没有研究中心
这种情况下,直接发"入组咨询"往往会被回复"您所在地区没有中心"。更有效的做法是申请同情用药/扩展准入(由主治医生一同提出),或询问能否到最近的境外中心参加。下面已为您切换到对应的信件版本。
查看完整申请路径与成功率说明 →总联系人(申办方/研究总部)
- Allison Boneallison.bone@monash.edu+61 3 9903 0343
- Tony Trapanitony.trapani@monash.edu+61 3 9903 0343
研究中心联系方式
- St Vincent's Health SydneySydney,New South Wales,Australia
- Prince of Wales HospitalSydney,New South Wales,Australia
- Blacktown HospitalSydney,New South Wales,Australia
- Royal Prince Alfred HospitalSydney,New South Wales,Australia
- Wollongong Hospital, Illawarra Shoalhaven HealthWollongong,New South Wales,Australia
- Sunshine Coast University HospitalBirtinya,Queensland,Australia
问自己是否符合条件、如何预筛
我的病情档案
档案只保存在您自己的浏览器里,不会上传,任何人(包括本站)都看不到。
英文版(发给研究团队)
Dear Study Team, I am a patient in China and I am interested in participating in your clinical trial: Study Title: Bone Loss Prevention With Zoledronic Acid or Denosumab in Critically Ill Adults ClinicalTrials.gov Identifier: NCT04608630 Sponsor: Australian and New Zealand Intensive Care Research Centre Investigational product: Denosumab 60 MG/ML, Zoledronic Acid 5Mg/Bag 100Ml Inj, Sodium Chloride 0.9% or 5% Dextrose Intravenous, Sodium Chloride 0.9% Injection About me: - Age: (please fill in) - Sex: (please fill in) - Confirmed diagnosis and stage: (please fill in) - Biomarkers / genetic testing: not available - Prior and current treatments: (please fill in) - Performance status (ECOG): not assessed - Current location: China - Travel ability: (please fill in) Could you please let me know: 1. Whether I might be eligible for this study; 2. Which site would be closest and most practical for me, and whether remote pre-screening is possible; 3. What documents (medical records, pathology or imaging reports, recent labs) I should prepare for pre-screening. I can provide English translations of my medical records. Thank you very much for your time and help. Kind regards, (your name) (your email / phone with country code)
中文对照(供您核对)
尊敬的研究团队: 我是一位来自中国的患者,希望咨询参加以下临床试验的可能: 研究名称:Bone Loss Prevention With Zoledronic Acid or Denosumab in Critically Ill Adults 试验编号:NCT04608630 申办方:Australian and New Zealand Intensive Care Research Centre 研究药物:Denosumab 60 MG/ML、Zoledronic Acid 5Mg/Bag 100Ml Inj、Sodium Chloride 0.9% or 5% Dextrose Intravenous、Sodium Chloride 0.9% Injection 我的基本情况: - 年龄:(请填写) - 性别:(请填写) - 确诊疾病与分期:(请填写) - 基因/标志物检测:暂无 - 既往及当前治疗:(请填写) - 体能状态(ECOG):未评估 - 目前所在城市:中国 - 可前往范围:(请填写) 想请教三个问题: 1. 我是否可能符合本研究的入组标准? 2. 哪个中心对我最方便可行?能否远程预筛? 3. 预筛需要准备哪些资料(病历、病理、影像、近期化验)? 我可以提供英文翻译版病历。感谢您的时间与帮助。 顺祝安康 (您的姓名) (您的邮箱/带国际区号的电话)
提示:请与主治医生一起发信——由医生署名的申请,回复率远高于患者单独发信。首封邮件不要附身份证号等敏感信息。研究团队通常在 3–10 个工作日内回复,两周无回音可礼貌追问一次。
下一步怎么做?
- 把本页信息带给您的主治医生,评估是否适合参加。
- 点击下方按钮打开官方注册页,查看研究中心联系方式。
- 直接联系研究团队咨询报名事宜(通常有中文同声翻译服务可协助沟通)。